ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, a gene therapy product candidate to treat patients with recurrent glioblastoma. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has collaboration agreements with Precigen, Inc., MD Anderson Cancer Center, the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ZIOP
CUSIP98973P10
Phone617-259-1970
Debt
Debt-to-Equity RatioN/A
Current Ratio7.17
Quick Ratio7.17
Price-To-Earnings
Trailing P/E Ratio-5.87
Forward P/E Ratio-5.98
P/E GrowthN/A
Sales & Book Value
Annual Sales$6.39 million
Price / Sales69.43
Cash FlowN/A
Price / CashN/A
Book Value($0.68) per share
Price / Book-4.57
Profitability
EPS (Most Recent Fiscal Year)($0.53)
Net Income$-54,320,000.00
Net Margins-1,212.13%
Return on EquityN/A
Return on Assets-54.86%
Miscellaneous
Employees46
Outstanding Shares142,650,000
Market Cap$443.65
ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
How were ZIOPHARM Oncology's earnings last quarter?
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) posted its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.02. The biotechnology company earned $0.15 million during the quarter, compared to the consensus estimate of $1.55 million. View ZIOPHARM Oncology's Earnings History.
When is ZIOPHARM Oncology's next earnings date?
What price target have analysts set for ZIOP?
3 Wall Street analysts have issued 12 month price targets for ZIOPHARM Oncology's shares. Their predictions range from $5.50 to $5.50. On average, they anticipate ZIOPHARM Oncology's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 76.8% from the stock's current price. View Analyst Ratings for ZIOPHARM Oncology.
What is the consensus analysts' recommendation for ZIOPHARM Oncology?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about ZIOPHARM Oncology stock?
Here are some recent quotes from research analysts about ZIOPHARM Oncology stock:
- 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (5/16/2018)
- 2. HC Wainwright analysts commented, "We note that the biopsy analysis from the tumors of patients with rGBM, presented at SNO 2017, showed that Ad-RTS-hIL-12 plus veledimex monotherapy led to upregulation of PD-1 and PD-L1 receptors, suggesting a potential synergy between IL-12 and anti-PD-1 agents. Together with the shift to combinations, management also intends to expand the Ad-RTS-hIL-12 program beyond recurrent glioblastoma (rGBM) to include additional oncologic indications, such as breast cancer and melanoma. We note that the company plans to present an update of the biopsy analysis from the patients with rGBM and advanced breast cancer treated with Ad- RTS-hIL-12 plus veledimex at ASCO on June 4, 2018." (5/14/2018)
Are investors shorting ZIOPHARM Oncology?
ZIOPHARM Oncology saw a increase in short interest in June. As of June 29th, there was short interest totalling 35,788,182 shares, an increase of 0.9% from the June 15th total of 35,453,583 shares. Based on an average daily trading volume, of 2,510,629 shares, the short-interest ratio is currently 14.3 days. Currently, 28.0% of the shares of the stock are sold short. View ZIOPHARM Oncology's Current Options Chain.
Who are some of ZIOPHARM Oncology's key competitors?
Some companies that are related to ZIOPHARM Oncology include Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), Biohaven Pharmaceutical (BHVN), ARMO Biosciences (ARMO), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Uniqure (QURE), TherapeuticsMD (TXMD), Theravance Biopharma (TBPH), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX) and G1 Therapeutics (GTHX).
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the folowing people:
- Dr. Laurence James Neil Cooper Ph.D., M.D., Chief Exec. Officer (Age 53)
- Mr. Kevin G. Lafond, Sr. VP of Fin., CFO, Chief Accounting Officer, Treasurer & Corp. Controller (Age 62)
- Dr. Francois Lebel M.D., Chief Medical Officer and Exec. VP of R&D (Age 66)
- Dr. David M. Mauney M.D., Exec. VP, Chief Bus. Officer & Interim COO (Age 49)
- Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.
Has ZIOPHARM Oncology been receiving favorable news coverage?
Press coverage about ZIOP stock has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ZIOPHARM Oncology earned a news sentiment score of 0.22 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.49 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are ZIOPHARM Oncology's major shareholders?
ZIOPHARM Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Chessman Wealth Strategies RIA (0.05%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for ZIOPHARM Oncology.
Which institutional investors are buying ZIOPHARM Oncology stock?
ZIOP stock was bought by a variety of institutional investors in the last quarter, including Chessman Wealth Strategies RIA. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for ZIOPHARM Oncology.
How do I buy shares of ZIOPHARM Oncology?
Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZIOPHARM Oncology's stock price today?
One share of ZIOP stock can currently be purchased for approximately $3.11.
How big of a company is ZIOPHARM Oncology?
ZIOPHARM Oncology has a market capitalization of $443.65 million and generates $6.39 million in revenue each year. The biotechnology company earns $-54,320,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. ZIOPHARM Oncology employs 46 workers across the globe.
How can I contact ZIOPHARM Oncology?
ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34 NAVY YARD PLAZA, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]
MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
